- China's Clover Biopharmaceuticals said on Monday it has ended its joint venture with GlaxoSmithKline Plc. GSK.L to develop a COVID-19 vaccine using the British drug maker's adjuvant, even as early-stage trials showed good results.
- The decision marks a further upset to GSK which said in December that clinical trials of a rival COVID-19 vaccine developed by it and Sanofi SASY.PA showed an incomplete immunity in older p....
Tags : Clover biopharmaceutical, GlaxoSmithKline, GSK, Dynavax, COVID-19 partnership, coronavirus, epidemic,
4 Min read